"Even with more rational.growth expectations, MAKO could still be a winning stock," writes SA...

"Even with more rational...growth expectations, MAKO could still be a winning stock," writes SA author Stephen Simpson after the company's sales warning yesterday, which has sent the shares into a 40% tailspin. However, "the burden is now back on management to prove that the RIO is an in-demand system" that really is needed.

Comments (1)
  • cjoe29
    , contributor
    Comments (177) | Send Message
    I agree. What I find interesting is the company continues to sell RIO's. CAPEX is down across the industry. The economy is slowing. I do see networks that want the RIO's buying in bulk before the medical device tax kicks in. The CEO did say surgeon training was booked thru November. Someone obviously likes it. :)
    10 Jul 2012, 11:08 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs